SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 15, 2026

COLL

COLLEGIUM PHARMACEUTICAL, INC
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $485K total
Actionable Insight • Neutral

The insider sales are routine director-level diversification and do not signal bearish conviction. The strong Q1 earnings and reaffirmed guidance support the current business trajectory. Monitor the AZSTARYS acquisition close and any post-close guidance update for the combined entity.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$33.65
T+0 close · May 15, 2026 · via day close
Latest settled
−23.63%
T+60 · $25.70
Vs SPY
−28.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $33.65entry
  2. T+1 · 6mo ago −0.09%α +0.56% · $33.62
  3. T+5 · 6mo ago +0.39%α −1.23% · $33.78
  4. T+20 · 5mo ago +2.97%α +1.39% · $34.65
  5. T+60 · 3mo ago −23.63%α −28.48% · $25.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two directors at Collegium Pharmaceutical sold a combined $485K in open-market stock within 11 days of the company reporting strong Q1 2026 earnings (revenue +9% YoY, JORNAY PM +36%). The sales are small relative to the $1.1B market cap (~0.04%) and are not clustered with C-suite insiders, making them routine diversification trades rather than informed selling. The earnings report reaffirmed full-year guidance and highlighted the pending AZSTARYS acquisition, which is expected to close in Q2 2026.

Key Financial Metrics

Direction
selling
Total Value
$485.0K
Insiders
2

Key Facts

  • Two directors sold a total of $485K in open-market shares over 4 days (May 11-13, 2026).
  • Sales represent ~0.04% of Collegium's $1.1B market cap, immaterial.
  • No C-suite insiders (CEO, CFO, etc.) sold shares in the cluster.
  • Q1 2026 earnings (filed May 7) showed net revenue of $193.5M (+9% YoY) and JORNAY PM revenue of $38.9M (+36% YoY).
  • Full-year 2026 guidance reaffirmed: Product Revenues $805-825M, Adjusted EBITDA $455-475M.
  • Pending AZSTARYS acquisition for $650M cash expected to close in Q2 2026.

Financial Impact

Insider sales of $485K are trivial relative to $1.1B market cap, no material financial impact.

Risk Factors

  • AZSTARYS acquisition integration risk and $650M cash outlay could pressure balance sheet.
  • Pain portfolio revenue growth is modest (+4% YoY) and faces generic competition risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-COLL-1779135356733

Track record

24 reports on COLL

Performance horizon

1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
  2. Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
  4. Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
  5. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  6. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
  8. Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  9. Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
  10. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026